drugset / Trial / NCT00975221

Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy

NCT00975221

Phase 3 Completed 67 enrolled Amgen
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is designed to demonstrate the efficacy and to assess the safety of cinacalcet for the reduction of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy is indicated on the basis of an elevated corrected total serum calcium, but who are unable to undergo parathyroidectomy.

Timeline

Start
2010-03-10
Primary completion
2012-07-12
Completion
2012-12-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Cinacalcet Other / unclassified 90 mg Oral